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Abstract
Early-stage detection of leukemia is a critical determinant for successful treatment of the disease and can increase
the survival rate of leukemia patients. The factors limiting the current screening approaches to leukemia include low
sensitivity and specificity, high costs, and a low participation rate. An approach based on novel and innovative
biomarkers with high accuracy from peripheral blood offers a comfortable and appealing alternative to patients,
potentially leading to a higher participation rate.
Recently, non-coding RNAs due to their involvement in vital oncogenic processes such as differentiation,
proliferation, migration, angiogenesis and apoptosis have attracted much attention as potential diagnostic and
prognostic biomarkers in leukemia. Emerging lines of evidence have shown that the mutational spectrum and
dysregulated expression of non-coding RNA genes are closely associated with the development and progression of
various cancers, including leukemia. In this review, we highlight the expression and functional roles of different
types of non-coding RNAs in leukemia and discuss their potential clinical applications as diagnostic or prognostic
biomarkers and therapeutic targets.
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Introduction
Leukemia is a class of blood cancers characterized by an
oligoclonal expansion of hematopoietic cells that infiltrate
the bone marrow and can also invade the blood and other
extramedullary tissues [1]. The proliferation of leukemic
cells causes the expulsion of the normal hematopoietic
cells and the loss of their functions, leading to severe
symptoms, including thrombocytopenia, anemia, and im-
munodeficiency. Hematological cancers are ranked as the
11th common type of cancer and the 10th common cause
of cancer-related death. More than 350,000 new leukemia
cases and 265,000 leukemia deaths were estimated to have
occurred in 2012 [2]. In the United States, leukemia ac-
counts for approximately 4% of cancer-derived mortalities
and 3.5% of all cancer cases. The incidence, mortality, and
survival of leukemia depends on the diagnosis, prognosis,
as well as natural history of neoplasms arising from the
malignant transformation of hemopoietic stem cells or
progenitor cells in the bone marrow [3].
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Leukemia can be classified according to its progression
pattern (acute or chronic) and affected lineage (lymph-
oid or myeloid). The four major subtypes are acute
lymphoblastic leukemia (ALL), chronic lymphoblastic
leukemia (CLL), acute myeloid leukemia (AML), and
chronic myeloid leukemia (CML) [4, 5]. ALL is one of
the most common types of malignancy in children
worldwide [6], while the other subtypes are more com-
mon in adults. In all types of leukemia, the abnormal
proliferation of bone marrow and blood cells interferes
with the production of functionally healthy cells. Thus,
anemia ensues in people with leukemia resulting in re-
duced ability to fight infections and clotting disorders.
For most patients, the causes of leukemia and its sub-
types are unclear partly due to diverse abnormalities and
multiple risk factors. However, the genetic background
interacting with environmental factors including expos-
ure to high doses of radiation or carcinogenic agents,
such as benzene; parental occupational exposures; and
infections all contribute to a higher risk of developing
leukemia [7].
The underlying molecular mechanisms mediating the
pathophysiology of leukemia are not fully understood.
Thus, deeper insights in the genetic basis of the disease
and their influence on the progress of the disease and
treatment response are crucial to discovering new prog-
nostic markers and novel therapeutic targets that can
open new doors in personalizing treatment. The focus of
research for decades has been on the expression of mes-
senger RNAs that code for proteins. Recently, there has
been much research suggesting that protein-coding
genes only cover a small proportion of the human tran-
scriptome and that a more significant proportion of the
human transcriptome (66%) is composed of long non-
coding RNAs (long ncRNAs), antisense and micro RNAs
(miRNAs), and pseudogenes [8]. Current evidence has
shown that ncRNAs might act as a link between the gen-
ome and the environment by being an intricate player in
the process of gene expression, contributing to the
pathogenesis of various human diseases, including can-
cer. Several studies have documented the involvement of
ncRNAs in differentiation, proliferation, and apoptosis of
leukemic cells and their potential as a future prognostic
biomarker.
In the current review, we discussed the characteristics
and role of leukemia related non-coding RNAs. We pro-
vided a succinct overview of the current understanding
of non-coding RNA expression patterns in different
types of leukemia, the mechanisms that contribute to
leukemia carcinogenesis, and their role in drug resist-
ance. Deciphering the essential role of diverse non-
coding RNAs may improvise the understanding of the
underlying biological events, ultimately leading to the
identification of novel therapeutic targets, opening new
prospects for treatment, diagnosis, and prognostication
of different types of leukemia.
Non-coding RNA networks and leukemia
Currently, there is an overpowering proof showing that
transcriptional, posttranscriptional and translational
controls, mediated by different non-coding RNAs, apply
necessary pleiotropic activities on various highlights of
leukemia science. This has opened space for disclosure
and portrayal of non-coding RNAs as biomarkers in
leukemia and prompted several investigations in this
field over the last 10 years. The full picture of these un-
usually communicating non-coding RNAs in leukemia is
slowly developing [9–17]. The vital role and underlying
molecular mechanisms of non-coding RNAs and their
therapeutic potential in leukemia are outlined in
Table 1.
Characteristics of non-coding RNA networks
Latest proceedings in high-throughput sequencing for
whole genomes and transcriptomes demonstrated that
fewer than 2% of the entire human genome encodes pro-
teins, whereas a large portion of the human genome,
constituting at least 75%, encodes ncRNAs [74]. Cur-
rently, ncRNAs are classified according to transcript size
into two broad categories, small (< 200 nucleotides;
ncRNAs) and long (> 200 nucleotides; lncRNAs) non-
coding RNAs (lncRNAs) (Fig. 1). The ncRNAs play a
major role in the process of gene expression, RNA mat-
uration, and protein synthesis [75–77]. With the emer-
ging evidence, it has become quite evident that not only
protein-coding mutations but variations within the non-
coding genome are also responsible for various cancer
etiologies [78, 79].
Long non-coding RNAs
lncRNAs are defined as transcripts with lengths exceed-
ing 200 nucleotides that are not translated into protein
[80, 81], and most of them are markedly expressed in
differentiated tissues or particular cancer types [78].
RNA polymerase II is responsible for executing the tran-
scription of lncRNAs, and generally, they are expressed
in a tissue-specific manner [78, 82]. LncRNAs regulate
several biological processes such as differentiation, de-
velopment and biogenesis and multiple human disor-
ders, including certain malignancies are associated with
deregulation of lncRNAs. Deregulation of lncRNAs was
demonstrated to be intrinsically connected with human
illnesses, including different kinds of malignant growths
[78, 82]. Because of this, lncRNAs have become a focal
point of researchers, and practical explanations of the
roles of lncRNAs are an evolving line of research. Usu-
ally, lncRNAs utilize various instruments to implement
their functions at a cellular level. For example, lncRNAs
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Table 1 Roles of ncRNAs implicated in leukemia
Type of ncRNA ncRNA Type of leukemia Expression in leukemia Mechanism/target/pathway References
miRNA miR-194-5p AML Upregulated inducing BCLAF1; BCL2-associated
transcription factor 1 (BCLAF1)
[18]
miRNA miR-103 AML Upregulated Blocking PI3K/AKT signal pathway by
regulation of COP1
[19]
miRNA miR-15a CML-CP Upregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-130b CML-CP Downregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-145 CML-CP Upregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-16 CML-CP Downregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-26a CML-CP Downregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-146a CML-CP Downregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-29c CML-CP Downregulated Expression modulated by BCR–ABL is linked
to CML progression and imatinib resistance
[20]
miRNA miR-96 AML Downregulated Oncogene Metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1)
knockdown inhibited proliferation,
promoted apoptosis and enhanced
Ara-C sensitivity in AML cells by
upregulating miR-96
[21]
miRNA miR-128b ALL Downregulated downregulation of the MLL-AF4 chimeric
fusion proteins MLL-AF4 and AF4-MLL that
are generated by chromosomal
translocation t(4;11)
[22]
miRNA miR-34a AML Downregulated TUG1 confers Adriamycin resistance in
acute myeloid leukemia by epigenetically
suppressing miR-34a expression via EZH2
[23, 24]
miRNA miR-451a CML Downregulated NR [25]
miRNA let-7b-5p CML Downregulated NR [25]
miRNA hsa-miR-425 AML Upregulated Through calcium signaling pathway and
natural killer cell mediated cytotoxicity.
[26]
miRNA hsa-miR- 200c AML Downregulated NR [26, 27]
miRNA hsa-mir-30a CML Downregulated NR [28]
miRNA miRNA-155 ALL Upregulated NR [29]
miRNA miR-130a CML Downregulated Functions as a tumor suppressor by
inhibiting multiple anti-apoptosis proteins,
including BCL-2, MCL-1 and XIAP.
[30]
miRNA miR-125b AML; ALL Upregulated microRNA125b promotes leukemia cell
resistance to daunorubicin through
inhibiting apoptosis
[31]
miRNA miR-224 CML Downregulated miR-224, along with let-7i, regulate the
proliferation and chemosensitivity of CML
cells probably via targeting ST3GAL IV.
[32]
lncRNA HOXA-AS2 AML Upregulated HOXA-AS2 negatively regulates the
expression of miR-520c-3p in ADR cells.
S100A4 was predicted as a downstream
target of miR-520c-3p,
[33]
lncRNA TUG1 AML Upregulated TUG1 confers Adriamycin resistance in
acute myeloid leukemia by epigenetically
suppressing miR-34a expression via EZH2
[23, 34]
lncRNA RP11-342 M1.7 AML Upregulated Involved in neoplastic signaling pathways [35]
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Table 1 Roles of ncRNAs implicated in leukemia (Continued)
Type of ncRNA ncRNA Type of leukemia Expression in leukemia Mechanism/target/pathway References
lncRNA CDCA4P3 AML Upregulated Involved in neoplastic signaling pathways [35]
lncRNA CES1P1 AML Downregulated Involved in neoplastic signaling pathways [35]
lncRNA AC008753.6 AML Downregulated Involved in neoplastic signaling pathways [35]
lncRNA RP11-573G6.10 AML Downregulated Involved in neoplastic signaling pathways [35]
lncRNA MEG3 CML Downregulated contributes to imatinib resistance through
regulating miR-21
[36]
lncRNA PANDAR AML Upregulated NR [37]
lncRNA GAS5 AML Upregulated Via affecting hematopoietic reconstitution [38]
lncRNA UCA1 CML Upregulated UCA1acts as a ceRNA Against miR-16 in
Chronic Myeloid Leukemia Cells
[39]
lncRNA MALAT1 CML Upregulated MALAT1 promotes imatinib resistance of
CML cells by targeting miR-328
[40]
lncRNA UCA1 AML Upregulated knockdown of UCA1 plays a role in
overcoming the chemoresistance of
pediatric AML, by inhibiting glycolysis
through regulating the miR-125a/HK2
pathway.
[41]
lncRNA NONHSAT076891 APL Upregulated NR [42]
lncRNA CRNDE AML Upregulated NR [13]
lncRNA LINC00899 AML Upregulated NR [12]
lncRNA HOTAIR CML Upregulated Knockdown of HOTAIR expression
downregulates MRP1 expression levels
and reverses imatinib resistance via
PI3K/Akt pathway.
[43]
lncRNA IRAIN AML Downregulated Interaction with chromatin DNA and
involvement in the formation of an
intrachromosomal promoter loop
[44]
lncRNA CCDC26 AML Upregulated NR [45]
lncRNA KCNQ1OT1 AML Upregulated NR [46]
lncRNA NONHSAT027612.2 ALL Upregulated Through regulating immune
response-associated pathways.
[47]
lncRNA NONHSAT134556.2 ALL Upregulated Through regulating immune
response-associated pathways.
[47]
lncRNA LINP1 AML Upregulated Via HNF4alpha/AMPK/WNT5A
signaling pathway
[48]
lncRNA SNHG3 AML Upregulated SNHG3 elicits a growth-promoting
function in AML via sponging
miR-758-3p to regulate SRGN
expression
[49]
lncRNA LUNAR1 ALL Downregulated Proliferation of T cells [50, 51]
lncRNA T-ALL-R-LncR1 ALL Upregulated Regulate apoptosis by Par-4/THAP1
protein complex
[52]
lncRNA HOTAIRM1 AML Upregulated Chromatin modification, myeloid
differentiation
[53, 54]
lncRNA PVT1 AML Upregulated Oncogene, induce proliferation and
suppress Apoptosis
[55]
lncRNA ANRIL AML/ALL Upregulated Myeloblast proliferation [56]
lncRNA BGL3 CML Upregulated Apoptosis and DNA methylation [57]
circRNA f-circPR AML Upregulated High proliferation, chemo resistance,
Differential expression
[58]
circRNA circ-PVT1 AML Upregulated Involved in the development of
leukaemia (AML)
[59]
Bhat et al. Molecular Cancer           (2020) 19:57 Page 4 of 21
can influence chromatin redesigning and methylation,
act as a miRNA restraint sponge, and regulate protein
complexes stability [76, 83, 84] (Fig. 2).
Several pieces of evidence have shown that some
lncRNAs, for example, TARID, Kcnq1ot1, and
AS1DHRS4, engage DNA methyltransferases to alter
chromatin conformation or act to alter the position of
nucleosome through the SWI/SNF complex as observed
in SChLAP1 [85–87]. The histone methyltransferase
poly-comb repressive complex-2 (PRC2) is a widely
studied protein managed by ncRNAs and has shown as
an intermediary target of lncRNAs [88]. PRC2 appears
to play a role in inactivating chromatin through initiat-
ing the inhibitory H3K427me3 histone marks [88].
Also, chromatin alterations by specific lncRNAs, for
example, HOTTIP and CCAT1, results in tweaking
chromosome circling and influencing gene promoters
[89, 90]. The lncRNA Firre was demonstrated to be
crucial in maintaining inactivation of the X chromo-
some [91]. X-linked lncRNA Firre cohesion with the
chromatin remodelers, CTCF and attachment, is one of
the essential steps in the process and includes changing
chromatin confirmation during the inactivation of X
chromosome process. Subsequently, the inactive X
chromosome is positioned close to the nucleolus and
maintain H3K27me3 methylation [91]. Different
lncRNAs have their distinct inhibitory roles regulated
through the action of authoritative miRNAs, which can
seize the biomolecules and diminish their potential to
inhibit their targets [82].
Table 1 Roles of ncRNAs implicated in leukemia (Continued)
Type of ncRNA ncRNA Type of leukemia Expression in leukemia Mechanism/target/pathway References
circRNA circNPM1 75,001
(hsa_circ_0075001)
AML Upregulated NPM1/regulate myeloid differentiation
though miR-181,
[60]
circRNA circ-HIPK2 AML Downregulated Regulate differentiation though miR-124-3p [61]
circRNA circRNA-DLEU2 AML Upregulated Enhanced cell division, survival, and
proliferation with suppressed apoptosis
through miR-496/ PRKACB
[62]
circRNA hsa_circ_0004277 AML Downregulated Act as prognostic factor for survival
outcome in AML patients. Target multiple
miRNAs and Genes miR-138-5p, miR-30c-1-
3p, miR-892b, miR-571, miR-328-3p/SH3GL2,
PPARGC1A, PIP4K2C, SH2B3, ZNF275, and
ATP1B4
[63]
circRNA circ-CBFB CLL Upregulated regulating miR-607/FZD3/Wnt/beta-catenin
pathway
[64]
circRNA circ_0132266 CLL Downregulated circ_0132266 acts as a sponge of miR-337-
3p and regulates its activity, resulting in a
downstream change of target-gene PML,
influencing cell viability.
[65]
circRNA circPAN3 AML Upregulated circPAN3-miR-153-5p/miR-183-5p-XIAP axis;
circPAN3 may facilitate AML drug resistance
through regulating autophagy and
influencing expression of apoptosis-related
proteins
[66, 67]
circRNA circ_0009910 AML Upregulated knockdown of circ_0009910 inhibited AML
cell proliferation and induced apoptosis by
acting as a sponge for miR-20a-5p
[68]
circRNA circ_100053 CML Upregulated involved in imatinib resistance [69]
circRNA hsa_circ_0080145 CML Upregulated knockdown of hsa_circ_0080145
significantly suppressed CML cell
proliferation thorugh acting as a
sponge for miR-29b.
[70]
circRNA circ-ANAPC7 AML Upregulated circ-ANAPC7 targets the MiR-181 Family [71]
circRNA hsa_circ_0004277 AML Downregulated Increasing level of hsa_circ_0004277 by
chemotherapy was associated with
successful AML treatment
[63]
circRNA circBA9.3 CML Upregulated Chemoresistance, Oncogene, Induce cell
proliferation and supressed apoptosis
[72]
siRNA SKP2 AML Upregulated SKP2 inhibits the degradation of P27kip1
and down-regulates the expression of MRP
[73]
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The roles of miRNA in leukemia have been broadly
explored in recent years, but the utilitarian roles of
lncRNAs in such tumors are yet unclear. Numerous
lncRNAs are deregulated in different sorts of malignant
growths, including head and neck cancer [92]. Unmis-
takable expression profiles of lncRNA have been distin-
guished in leukemia [9, 33, 35, 45, 47–49, 93–99]. Some
of these have been demonstrated to have well-
understood jobs in the development and progression of
leukemia, suggesting the vital use of lncRNAs as novel
biomarkers and potential targets for the treatment of
leukemia. Recent shreds of evidence have demonstrated
that few lncRNAs play significant physiological roles and
are essential for regulating different levels of gene ex-
pression [84, 100, 101]. While some of the lncRNAs act
as oncogenes, others function as tumor suppressors, and
they are involved in cellular processes, including the cell
cycle and tumor invasion and metastasis [102]. For ex-
ample, the lncRNA HOXA cluster antisense RNA2
(HOXA-AS2), which has been previously shown to have
oncogenic properties in several human malignancies,
was found to diminish glucocorticoid sensitivity in acute
lymphoblastic leukemia through the HOXA3/EGFR/Ras/
Raf/MEK/ERK pathway [33]. Likewise, exhaustive
lncRNA expression profiling by RNA sequencing has
uncovered that lncRNA RP11-342M1.7, lncRNA
CES1P1 and lncRNA AC008753.6 are both independent
as well as in combination, serve as predictive factors for
AML risk [35]. LncRNA LINP1 was found to regulate
AML progression employing the HNF4alpha/AMPK/
WNT5A signaling pathway [48]. miR-335-3p dysregula-
tion, directed by the lncRNAs NEAT1 and MALAT1, is
associated with a poor prognosis in childhood ALL. By
and large, these discoveries provide a greater depth of
understanding into the pathogenesis of a high-risk group
of leukemias that can help clinicians explore the possi-
bility of using lncRNAs for treatment.
Micro RNAs
Micro RNAs (miRNAs) are a subset of non-coding
RNAs ~ 19–20 nt in length with 5′-phosphate and 3′-
hydroxyl ends. The ribonuclease Dicer processes them
from precursors having a characteristic hairpin second-
ary structure (Fig. 3). miRNAs were first discovered in
Fig. 1 Classification of noncoding RNAs (ncRNAs). Noncoding RNAs are classified into small ncRNAs (< 200 nucleotides) or long ncRNAs (> 200
nucleotides) based on their length. Small ncRNAs are further classified into functional and regulatory noncoding RNAs while long ncRNAs are
classified based on their structure, function and location
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Caenorhabditis elegans and have since been found in
most eukaryotes, including humans [103–105]. Accord-
ing to the reports, human genome comprised of approxi-
mately 1–5% of miRNA, which is responsible for at least
30% of the protein-coding genes [106–110]. To date,
940 distinct miRNA molecules have been identified
[111–113]. The knowledge about the specific targets and
biological functions of miRNA molecules is still scarce,
but their crucial role in the regulation of gene expres-
sion, controlling diverse cellular and metabolic pathways
is well-evident [114–119]. As this field is still emerging,
there are only a limited number of studies in the context
of miRNAs in leukemia.
While some of the miRNAs work as oncogenes, others
work as tumor suppressors [120]. For instance, it has
been shown that the balance between miR-194-5p and
its target BCL2-associated transcription factor 1
(BCLAF1) is commonly deregulated in AML patients
[18]. Also, miR-10a-5p was found to be overexpressed in
relapsed AML cases [121]. Furthermore, the expression
of miR-96 was downregulated in newly diagnosed AML
and is associated with leukemic burden [122]. Collect-
ively, these findings allow us to develop a better under-
standing of the underlying mechanisms of a high-risk
group of leukemias that can assist clinicians in clarifying
the function of miRNA and use this information to
guide treatment.
Role of microRNA gene abnormalities in leukemia
Abnormal expression of miRNA has been reported in many
malignancies, including stomach [123], brain [124], breast
[125], lung [126], liver [127], colon [128], leukemia [129]
and lymphoma [130]. Many studies have reported that
microRNA function as a tumor suppressor or oncogene. In
most of the tumors, the tumor -suppressing miRNAs are
downregulated, whereas the oncogenic miRNAs are overex-
pressed. Jongen-Lavrencic et al., [131] reported that miR-
155 is upregulated in hematopoietic stem cells carrying
FLT3-ITD and nucleophosmin (NPM1) gene mutations of
AML patients. Similarly, Lagos-Quintana et al., [132] in
murine lymphocyte precursors reported increased expres-
sion of miR-155 that induces polyclonal lymphocytosis and
develops high-grade lymphocytic leukemia. Also, in the
case of a myeloproliferative disease, the overexpression of
miR-155 was reported that leads to increased granulocyte-
monocyte cells [122]. Fuster O et al., [133] suggested that
abnormal expression of miR-155 signaling targets SHIP1
and CEBPB in AML patients, both of which are critical in
granulopoiesis. Yamamoto et al., [134] reported that miR-
133 in leukemic cells targets the Ecotropic viral integration
Fig. 2 General mechanisms for functions of Long Noncoding RNAs. Nuclear lncRNAs are implicated in Epigenetic regulations, Transcriptional
regulations, and splicing regulations while cytoplasmic lncRNAs are involved in mRNA stability, act as small regulatory RNA sponges, regulate
mRNA translation and can also be small peptide producers
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site 1 (Evi1) which upregulated the drug sensitivity and sug-
gested that miR-133 can be a potential therapeutic target
for Evi1-overexpressing leukemia. In AML cell lines, Xiao
et al. [135] reported elevated expression of miR-223 that
inhibited proliferation and cell motility but promote cell
apoptosis. Several studies reported that ectopic miR-223
overexpression decreased the tumorigenesis by controlling
the G1/S cell cycle phase transition [136]. Lin X et al., [137]
investigated that the miR-370 expression was decreased in
pediatric AML patients which in turn contribute to the sig-
nificant progression of the disease and it was suggested that
the miR-370 expression could act as non-invasive diagnos-
tic and, a prognostic marker for pediatric AML patients.
Magee P et al. has reported [138] that abnormal expression
of microRNAs induce chemoresistance that affects a variety
of cancer types and he also determined that the forced ex-
pression of miR-22 and miR-193a leads to inhibition of
leukemia progression. Liu X et al., [139] conducted
experiments in leukemic cell lines HL60, NB4, and K562
and reported that the upregulation of miR-181a induces
higher cell proliferation thereby increased cell cycling by
targeting ATM. It has been investigated that the transfec-
tion of miR-128 increased the drug sensitivity, enhanced
apoptosis in HL60 cell lines [140], whereas the DNA dam-
age was tolerated; however, the molecular mechanism is yet
to be elucidated. However, Volinia S et al., [141] reported
that miR-128 to be overexpressed and upregulated in differ-
ent malignancies, but its expression was decreased in AML
cells carrying NPM1 mutations. Imatinib Resistance has
been reported as a major hurdle for the treatment of
chronic myeloid leukemia (CML). The miRNAs are in-
volved in various processes from the development to drug
resistance of tumors, including chronic myeloid leukemia
(CML). Recent data suggested that miR-221-STAT5 axis
played crucial roles in controlling the sensitivity of CML
cells to imatinib [142]. Another recent finding reports that
Fig. 3 MicroRNA (miRNA) biogenesis and regulation of gene expression. The series of events includes the production of the primary miRNA (pri-
miRNA) transcript by RNA polymerase II or III and cleavage of the pri-miRNA into a stem-loop structured miRNA precursor (pre-miRNA) by the
microprocessor complex Drosha-DGCR8 (Pasha) in the nucleus. Then the pre-miRNA hairpin is exported from the nucleus by Exportin-5-Ran-GTP.
In the cytoplasm, the RNase Dicer in complex with the double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to its mature
length. The functional strand of the mature miRNA is loaded together with Argonaute (Ago2) proteins into the RNA-induced silencing complex
(RISC), where it guides the RISC to silence target mRNAs through mRNA cleavage, translational repression or deadenylation, whereas the
passenger strand is degraded
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lncRNA MALAT1/miR-328 axis promotes the proliferation
and imatinib resistance of CML cells, providing new per-
spectives for the future study of MALAT1 as a therapeutic
target for CML [40]. In addition, miR-214 was associated
with the imatinib resistance in CML patients by regulating
ABCB1 expression [143].miR-30e has been shown to be
directly targeting ABL mRNA and leads to decreased trans-
lation of ABL protein [144]. In K562 cells, the increased ex-
pression of miRNA-30e induces apoptosis and suppresses
proliferation and sensitized the cells to imatinib treatment.
miR-203 enhances the sensitivity of CML patients to ima-
tinib and its expression was downregulated in bone marrow
of CML patients [145].
Circular RNAs
Circular RNAs (circRNAs) are an abundant class of regu-
latory transcripts primarily derived from protein-coding
exons and widely expressed across eukaryotic organisms,
including Homo sapiens and Mus musculus [146–150].
They play an essential role in regulating gene expression
[151] through forming covalently closed continuous loop
structures with no exposed ends. CircRNAs are evolution-
arily conserved, display a higher degree of relative stability
in the cytoplasm and are often expressed in a tissue/devel-
opmental stage-specific trend [152]. Briefly, circRNAs are
produced co-transcriptionally from precursor mRNA by
back-splicing of RNA polymerase II transcribed genes and
often expressed at only low levels. The biogenesis of cir-
cRNAs is regulated through cis and trans-acting regula-
tory elements that control splicing [153]. The structural
form of most circRNAs is composed of multiple exons,
and multiple circRNA isoforms can be expressed from a
gene with the inclusion or exclusion of internal introns
through alternative splicing [153–155].
Recent studies have shown that several circRNAs
play important physiological and functional roles at
multiple stages of the gene expression regulation cas-
cade [84, 100, 101]. CircRNAs are known to be
Fig. 4 General mechanisms for functions of circular RNAs (circRNAs). circRNAs can function as a sponge for a miRNA/RBP keeping miRNA/RBP
away (dashed arrows) from its mRNA targets, thus altering gene expression. Through interaction with U1 snRNP, exon-intron circRNAs (EIciRNAs)
can interact with transcription complexes at host genes to induce their transcription
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involved in post-transcriptional regulation by acting
as decoys for binding of micro RNAs, reducing their
cellular availability and resulting in the upregulation
of their target mRNAs (Fig. 4). For example, circRNA
ciRS-7, also known as CDR1as, is produced from the
vertebrate cerebellar degeneration-related 1 (CDR1)
antisense transcript and acts as an RNA sponge to re-
press miR-7 activity [148, 156]. Knockout mice of
CDR1as show defects in sensorimotor gating [157]
and knockdown of CDR1as expression results in a de-
crease of tumor growth and proliferation in cancer
cell lines [158, 159]. Another circular RNA produced
from the Sry gene has 16 binding sites for miR-138, and
overexpression constructs of Sry circRNA attenuate the
knockdown effects of miR-138 target mRNAs [156]. In-
deed, multiple studies have remarkably demonstrated the
potent sequestering effects of miRNA activity by cir-
cRNAs, making them excellent agents for competing en-
dogenous RNA activity [148, 156, 160–164]. Increasing
evidence also suggests that circular RNAs could perform
other functional roles such as storage or sequestration of
transcription factors and RNA binding proteins [165],
microRNA transport [157] or encode functional proteins
[166–169].
CircRNAs are altered in a variety of pathological con-
ditions, which has stimulated significant interest in their
role in human disease and cancer. There is emerging
evidence that circRNAs show close association with
many human diseases, including cancers – often but not
always involving micro RNA (miRNA) intermediate.
One study revealed hundreds of circRNAs being more
abundant in blood than corresponding linear mRNAs,
which suggests that circRNAs could be used as new bio-
markers in standard clinical blood samples [170]. For in-
stance, circ-CBFB was found to promote proliferation
and inhibit apoptosis in CML by regulating the miR-
607/FZD3/Wnt/beta-catenin pathway [171]. Addition-
ally, circ_0009910 was found to be significantly upregu-
lated in AML patients, and its high expression was
shown to be associated with poor outcomes of AML pa-
tients [68]. Similarly, hsa_circ_0080145 was found to
regulate CML cell proliferation by acting as a miR-29b
sponge, and its knockdown was found to suppress CML
cell proliferation [170] significantly. On the other hand,
circRNAs circ_0132266 and hsa_circ_0004277 were
found to be significantly downregulated in CLL and
AML, respectively [63, 65].
We have identified multiple circular RNAs that are
differentially expressed in metastatic versus primary
ovarian tumors [172]. These circRNAs exhibits a robust
expression pattern compared to their linear counterparts
with higher power to distinguish between tumor sub-
types. This may offer a more robust diagnostic marker
of disease progression and prognosis. Our new results
have indicated a substantial genetic control of the circu-
lar RNA expression that is mostly independent of the
basal gene expression [173]. The power to distinguish
between tumor subtypes along with an independent gen-
etic control mechanism for their expression strongly
points towards a functional and regulatory role for the
circular RNA structures and their potential to contribute
to disease pathogenicity. It is, therefore, worthwhile to
investigate the mechanisms for biogenesis of circRNAs
and their contribution to pathogenesis; this may lead to
the development of new therapeutic interventions and
biomarkers with diagnostic and prognostic capabilities.
Underlying mechanisms of chemoresistance
regulated by ncRNAs in leukemia
As in many cancers, resistance to therapy is a significant
problem in the treatment of leukemia patients. The most
commonly used chemotherapeutic drugs like bendamus-
tine, chlorambucil, and rituximab [174, 175] although
show initial response, but later on patients acquire resist-
ance to these therapeutic regimens, hence limiting their
efficacy. Also, many leukemia patients show resistance be-
fore treatment (intrinsic resistance) and therefore do not
even show initial response. While the molecular mecha-
nisms for both intrinsic and acquired resistance are mostly
unidentified, identification of unique targets and pathways
involved are still an area of intense investigation. Though
genetic and epigenetic modifications that result in dysreg-
ulation of multi drugs transporters, alterations of drug tar-
gets & metabolism of drugs, defects in apoptosis &
autophagy machinery, disruption of redox system, in-
creased DNA repair and increased stem cell populations.
Have been identified as mediators of drug resistance, the
exact mechanisms of drug resistance, cross-talk among
different mechanisms and their regulation are still under
investigation. Recently, studies have conclusively estab-
lished the role of miRNAs in chemotherapeutic resistance
in leukemia [176, 177]. These studies have shown the de-
regulation of many miRNAs and their association with re-
sistance to chemotherapy. For example, miR-181a and
miR-181b are downregulated in chronic lymphocytic
leukemia (CLL) [138] and overexpression of these miR-
NAs sensitize CLL cells to fludarabine mediated cell death
by targeting B-cell lymphoma − 2 (BCL − 2), myeloid cell
leukemia-1 (MCL-1) and X-linked inhibitor of apoptosis
protein (XIAP) [178]. Similarly, restoration of miR-181b
sensitize leukemia cells to doxorubicin (DOX) and cytara-
bine (ara-C) by downregulating MCL-1 and high mobility
group box-1 (HMGB1) expression [179]. On the contrary,
ectopic overexpression of miR-125b in leukemia cells in-
duced resistance to daunorubicin (DNR) and prevented
apoptosis by downregulating G-protein-coupled receptor
kinase 2 (GRK2) and p53 -upregulated modulator of
apoptosis (PUMA) [180].
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Chronic myeloid leukocyte (CML) is characterized by
the Philadelphia (Ph) chromosome [181] with fusion
protein breakpoint cluster region-Abelson murine
leukemia (BCR-ABL) tyrosine kinase overexpression.
Interestingly, Imatinib, an inhibitor of BCR-ABL, show
improved therapeutic efficacy in Ph-positive CML pa-
tients [182]. Interestingly, downregulation of ABL target-
ing miRNA-30e was reported in CML cell lines and
patient samples [182]. Furthermore, overexpression of
miRNA-30e in K562 leukemia cells suppressed prolifera-
tion, induced apoptosis and sensitized them to Imatinib
treatment. While miRNA-203 sensitizes CML cells to
Imanitib and induces apoptosis [145], miRNA-486, on
the other hand, promotes Imanitib resistance by target-
ing PTEN and FOXO1 [183].
While the intrinsic resistance is due to many factors,
including miRNA in our case, acquired resistance by
tumor cells is promoted in response to continuous drug
treatment. DNR and ara-C (anthracyclines) are most
commonly used and effective chemotherapeutic drugs
for leukemia treatment [184]. Though the use of these
drugs results in the complete remission of the disease,
most of the patients relapse within 5 years [185, 186],
while inefficient tumor cell targeting, mutagenic effects
of the drug or selection of resistant clones might be the
reasons for relapse and development of aggressive tu-
mors, however the underlying mechanism(s) are still to
be identified. These anthracyclines by intercalating into
the DNA and targeting Topoisomerase II [187, 188] hin-
der replication [189]. Interestingly, Topoisomerase II is
downregulated in drug-resistant AML subtypes [190,
191], thus making these tumors resistant to these drugs.
The topoisomerase II cuts DNA strands and binds to
the scaffold/matrix-associated protein region (S/MAR)
to prevent or resolve DNA supercoils. Therefore, anthra-
cycline treatment results in DNA double-strand breaks
which can be temporarily fixed by non-homologous end
joining leading to gene mutation and t4:11 is a common
mutation that occurs at S/MAR in AML [192–194]. S/
MARs by interacting with HDACs regulate expression of
miRNAs like miR-93, miR-221, miR-17, let-7b and miR-
17-92 cluster. While the dislocation or loss of S/MAR
can modulate miRNAs expression [195], anthracyclines
like daunorubicin can induce DNA damage associated
with deregulation of miRNA expression in leukemia.
Though anthracyclines by modulating miRNA expres-
sion regulate cell proliferation and apoptosis, specific
miRNAs modulate the DNA repair signaling pathway
components resulting in the development of therapeutic
resistance. In this connection, resistance to daunorubicin
(DNR) has been associated with overexpression of
miRNA-21 and its downregulation in resistant K562/
DNR cells enhanced DNR cytotoxicity in vitro. Similarly,
overexpression of miR-181a in HL60, NB4, and K562
cells by targeting ataxia telangiectasia mutated (ATM)
increased proliferation [139]. Also, miR-128 by targeting
Rad51 promoted DNA damage and sensitized AML
OCI-AML3 and MV4–11 cells to oral nucleoside analog
prodrug called sapacitabine [196]. Though upregulated
in many cancers, miR-128 is downregulated in AML, es-
pecially carrying NPM1 mutations [141, 197]. However,
ectopic overexpression of miR-128 in HL60 cells in-
creased drug sensitivity and promoted apoptosis [140].
In addition to miR-128, other miRNAs such as miR-103,
miR-107, and miR-506 have been found to target Rad51
in other cancers as well. More specifically, miRNA-125b
is overexpressed in pediatric acute promyelocytic
leukemia (APL) than in other subtypes of acute myelog-
enous leukemia (AML), and its exogenous expression in
AML cells imparted DOX resistance [198].
ABC transporters are most important proteins pro-
moting drug resistance in almost all the tumors. While
the above mentioned miRNAs impart drug resistance,
many other miRNAs that are involved in sensitizing can-
cer cells to therapeutic drugs by targeting ABC trans-
porters are downregulated in cancer [199]. In this
category, miR-326 was found to downregulate the ABC
transporter ABCC144 in resistant HepG2 cells and
sensitize them to chemotherapeutic drugs. In addition to
ABCC144, miR-326 also negatively regulated other ABC
family members such as ABCA2 and ABCA3, which are
drug-resistance related genes [200]. However, the miR-
326 expression is reported to be significantly downregu-
lated in the multidrug resistance (MDR+) pediatric ALL
patients compared to the (MRD-) group [27]. A recent
study showed upregulation of miR-125b-2 cluster (Let-
7c, miR-125b, and miR-99a) in leukemia patients with
ETV6-RUNX1+ fusion gene expression.
Further studies showed that knockdown of miR-125b
in REH ETV6-RUNX1+ cells result in increased sensitiv-
ity to staurosporine and doxorubicin treatment, while
overexpression of miR-125b-2 cluster inhibited apoptosis
and increased cell survival suggesting its therapeutic po-
tential in pediatric ALL [201]. In a recent comprehensive
study, the involvement of miRNAs in L-asparaginase (L-
ASP), vincristine (VCR), prednisolone (PRED) and DNR
resistance was investigated [202]. This study showed the
involvement of miR-454 in resistance to L-ASP, miR-
125b, miR-99a, & miR-100 to DNR and miR-125b to
VCR resistance. Furthermore, over expression of miR-
125b prevented VCR mediated apoptosis in vitro [202].
Interestingly, leukemia ETV6-RUNX1+ patients with
high expression of miR-125b show resistance to VCR
treatment. Like chemotherapeutic drugs, use of gluco-
corticoids (GCs) for clinical treatment of pediatric ALL
is also limited by the development of resistance resulting
in poor patient response. Involvement of miRNAs in re-
sistance/sensitivity to GC treatment has recently been
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evaluated [203]. In a genome-wide study, while the ex-
pression of miR-335 was found to be downregulated in
all pediatric ALL patients, its overexpression sensitized
ALL cells to PRED treatment in vitro [204]. In addition
to PRED, ALL cells with miR-335 overexpression
showed resistance to other chemotherapeutic drugs with
limited cell death [204]. Another miRNA, miR-210 is
differentially expressed in various types of cancers in-
cluding leukemia [205]. Using agomiR or antagomiR for
miR-210 in LEH cells (to either increase or decrease the
expression respectively) modulated the response to dexa-
methasone (DEX), L-ASP, VCR and DNR [205], suggest-
ing that use of agomiR’s/antagomiR’s can be a novel
alternative to overcome miRNA mediated therapeutic
resistance in cancers including leukemia [205].
Role of non-coding RNAs in immune modulation
in leukemia
Several ncRNAs, including miRNAs, lncRNAs and cir-
cRNAs have been implicated in the modulation of the im-
mune system in various human malignancies, including
leukemia. These ncRNAs can modulate immune system
either directly by regulating the differentiation of immune
cells or indirectly by regulating the expression of various
signaling molecules, including NF-kB, c-Myc, p53 and
Notch. In this section, we will discuss the available evi-
dence on the role of ncRNAs in immune modulation and
its implications in leukemia. Most leukemia are driven by
genetic or epigenetic abnormalities in hematopoietic stem
cells (HSCs) or progenitor cells, leading to differentiation
arrest and increased proliferation and survival of imma-
ture blasts in the bone marrow. In one of the first studies
on understanding the role of lncRNAs in early
hematopoietic differentiation, RNA sequencing of HSCs
led to the identification of two lncRNAs, lncHSC-1 and
lncHSC-2 [206]. Their depletion resulted in altered mye-
loid differentiation, impaired self-renewal of HSCs and in-
creased T cell differentiation [206]. These results indicate
that lncRNAs can regulate HSC differentiation, and any
deregulation in their expression might contribute to vari-
ous hematological malignancies by altering the differenti-
ation of various HSCs. Indeed, several ncRNAs have been
found to contribute to leukemogenesis through immune
modulation and altering cell differentiation. HOXA tran-
script antisense RNA, myeloid-specific 1 (HOTAIRM1) is
a myeloid-specific long intergenic non-coding RNA
(lincRNA), and it is upregulated during myeloid matur-
ation [207]. Knockdown of HOTAIRM1 in the human
acute promyelocytic leukemia (APL) cell line NB4 resulted
in decreased granulocytic maturation [53]. HOTAIRM1 is
known to regulate the expression of the HOX, CD11b and
CD18 genes, which are required for myeloid cell differen-
tiation [53]. Pathway analysis of HOTAIRM1 knockdown
NB4 cells treated or untreated with all-trans retinoic acid
(ATRA) revealed significant alterations in leukocyte medi-
ated immunity, MHC class I protein complex, comple-
ment control module and regulation of leukocyte
activation pathways [53]. Furthermore, HOTAIRM1 ex-
pression is also modulated by another transcription factor,
PU.1, during granulocyte differentiation [208]. PU.1 is a
master regulator of myeloid differentiation, while PU.1,
along with IRF8, is known to control the fates of follicular
(FO) and germinal centers (GO) B cells [209]. Double
knockout of IRF8 and PU.1 in B cells has been shown to
impair the development of FO and GC B cells [209]. This
signifies that HOTAIRM1 can modulate tumor immunity
in leukemia by interacting with other regulatory mole-
cules. PU.1 is also known to drive the expression of lnc-
DC, which is a lncRNA exclusively expressed in human
dendritic cells (DCs) and is required for the differentiation
of DCs [210]. Knockdown of lnc-DC resulted in impaired
DC differentiation and function, and these effects were
mediated by lnc-DC by regulating the posttranslational
modification of a critical DC transcription factor, STAT3
[210]. Some of the proteins found to be altered after lnc-
DC knockdown include those involved in antigen presen-
tation (HLA-DR), cytokine secretion (IL-12) and T cell ac-
tivation (CD40, CD80, and CD86). PU.1 also induces miR-
23-27-24 cluster and plays a vital role in the regulation of
immune cell lineage commitment [211].
Furthermore, this miRNA cluster regulates lymphoid
cell differentiation and promotes myeloid lineage com-
mitment and cell proliferation by directly targeting vari-
ous lymphoid transcription factors, including Runx1
[211]. A recent study has identified a lincRNA,
LINC00173, to be very specifically expressed in mature
granulocytes [212]. Knockdown of LINC00173 in human
CD34+ HSCs resulted in a defect in granulocytic differ-
entiation and an increase in myeloid precursors in vitro
[212]. Depletion of LINC00173 in NB4 leukemia cells,
which carry an intrinsic block of granulocytic differenti-
ation, resulted in reduced cell proliferation, signifying its
role in early myelopoiesis [212]. Functional studies re-
vealed the binding of LINC00173 with the EZH2 subunit
of PRC2 [212]. X-inactive specific transcript (Xist) is an-
other lncRNA reported in various human malignancies,
including leukemia. Conditional knockout of Xist in
murine hematopoietic cells resulted in myeloid leukemia
and other impairments such as bone marrow dysfunc-
tion, lymphoid organomegaly and lymphoid infiltration
of end organs [213]. Aforementioned examples
emphasize the importance of ncRNAs in regulating im-
mune cell differentiation, which is of great clinical rele-
vance in leukemia.
The tumor suppressor p53 is known to induce the ex-
pression of lncRNA activator of enhancer domains (LED)
in cancer [214]. The expression of LED is downregulated
in leukemia, possibly due to promoter hypermethylation
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[214]. Another lncRNA, encoded from the first intron of
the human p53 gene and known as lncRNAp53int1, is
shown to be highly expressed in undifferentiated human
myeloid leukemia cells [215]. However, expression of
lncRNAp53int1 is significantly reduced during terminal
differentiation of human leukemia cells into monocytes
and macrophages [215]. Since several drugs have been
used to induce differentiation of leukemia cells, targeting
of lncRNAp53int1 could offer a newer therapeutic ap-
proach for the management of leukemias. Induction of
p53 has also been shown to induce two other lncRNAs,
nuclear enriched abundant transcript 1 (NEAT1) and
lincRNA-p21, in primary human CLL [216]. The expres-
sion of NEAT1 is downregulated and seems to be regu-
lated by PML-RARα in APL [217]. NEAT1 is also found
to regulate myeloid differentiation in APL [217]. Recently,
pharmacological activation of p53 has been shown to in-
duce an immune-inflammatory response by activating NK
cells, leading to suppression of leukemia growth [218].
However, p53 activation also results in the overexpression
of PD-L1 in the surviving leukemia cells, promoting their
immune escape [218]. All these evidences suggest a crucial
role of p53 in regulating lncRNAs during immune modu-
lation in leukemia.
Enhancer RNAs (eRNAs) are another class of lncRNAs
and have been reported to be involved in immune
modulation. Brazao et al. identified three lncRNA loci
(LNCGme00432, LNCGme00344 and LNCGme00345),
all of which are eRNAs, in a mouse model of B-ALL
[219]. All of these eRNAs interact with PAX5, a tran-
scription factor required for B-cell development and as-
sociated with the development of B-ALL, and are
downstream of the B-cell lymphoma 11a (Bcl11a) gene
[219]. Since the Bcl11a gene is required for VDJ recom-
bination of immunoglobin genes and is also involved in
B-cell development, a role of these eRNAs along with
the PAX5 and Bcl11a genes in normal B-cell develop-
ment and immune modulation in B-ALL cannot be
ruled out.
In CLL, more than 50% of cases carry a deletion of the
critical region at 13q14.3 [220, 221]. In addition to various
tumor suppressor genes, miR-15a/16–1 and lncRNAs, de-
leted in lymphocytic leukemia 1 (DLEU1) and 2 (DLEU2),
are also transcribed from this locus [222]. The miRNAs
and lncRNAs have been reported to be deleted and epige-
netically regulated in CLL [222, 223]. Interestingly,
DLEU1 and DLEU2 are also known to regulate NF-kB ac-
tivity through other NF-kβ regulating genes. Furthermore,
the miR-15/16 family of genes is also known to induce
NF-kβ activity [222] strongly. In CLL, NF-kB signaling is
reported to be active, usually through interaction with the
tumor microenvironment (TME), which leads to the sur-
vival of leukemia cells [224]. Another lncRNA, p50-
associated COX-2, extragenic RNA (PACER), which is
transcribed from the upstream region of the human COX-
2 gene, regulates COX-2 expression by interacting with
the repressive p50 subunit of NF-kβ, thereby functioning
as a decoy lncRNA for NF-kB signaling [225]. NF-kB in-
duced lncRNA, linc-Cox2, coactivates NF-kB, leading to
induction of late-primary response genes in innate im-
mune cells [226]. Since the NF-kβ family of transcription
factors plays a crucial role in the regulation of tumor in-
flammation and immunity [227], we suggest that the NF-
kβ as mentioned above regulated ncRNAs might also
modulate immune system in leukemia.
Notch-regulated oncogenic lncRNA, leukemia-induced
non-coding activator RNA-1 (LUNAR1), has been iden-
tified in T-cell acute lymphoblastic leukemia (T-ALL)
[228]. Mechanistically, LUNAR1 regulates IGF signaling
and induces IGF1R expression, leading to the survival of
T-ALL cells [228]. The expression of LUNAR1 is upreg-
ulated in primary T-ALL cells, more so in Notch mu-
tated samples, whereas its expression is suppressed upon
Notch inhibition [228]. Another lncRNA, NOTCH1 as-
sociated lncRNA in T ALL (NALT), is also found to be
associated with the Notch1 gene and functions as a tran-
scription factor to activate Notch signaling and promote
cell proliferation in pediatric T-ALL cells [229]. Role of
Notch signaling in normal and effector immune cell dif-
ferentiation is well established [230]. Furthermore,
Notch can regulate various components of TME, includ-
ing immune cells, fibroblasts, endothelial, and mesen-
chymal cells [230]. Since Notch signaling is also involved
in human T-ALL [228, 229], we believe that Notch-
regulated lncRNAs can potentially modulate immune
system in leukemia.
Beta Globin Locus 3 (BGL3) is a lncRNA that regu-
lates Bcr-Abl mediated cellular transformation in CML
[57]. Bcr-Abl has been found to negatively regulated
BGL3 expression through c-Myc-dependent DNA
methylation in CML [57]. Interestingly, BGL3 acts as a
competitive endogenous RNA (ceRNA), and it is tar-
geted by many PTEN regulating miRNAs, including
miR-17, miR-93, miR-20a, miR-20b, miR-106a and miR-
106b [57]. It is well known that loss of PTEN in cancer
cells leads to an immunosuppressive microenvironment
through secretion of various immunosuppressive cyto-
kines, recruitment of myeloid-derive suppressor cells
(MDSCs) and regulatory T-cells (Tregs), and inhibition
of CD8+ T-cell killing [231]. Hence, we speculate that
BGL3 might also lead to immune modulation in
leukemia through PTEN and PTEN-regulating miRNAs,
although this needs to be experimentally proven. Colon
cancer-associated transcript-1 (CCAT1) is a lncRNA
that is known to be highly expressed in adult AML
[153]. CCAT1 represses monocytic differentiation and
promotes leukemia cell growth by upregulating onco-
genic c-Myc and suppressing tumor suppressive miR-
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155 [153]. c-Myc is also known to induce lncRNA H19
expression in leukemia cells, thereby promoting cell pro-
liferation and survival [232]. Plasmacytoma variant
translocation 1 (PVT1) is another lncRNA that exerts its
oncogenic effects by stabilizing the c-Myc protein in
cancer [233]. Furthermore, in leukemia and other solid
tumors, c-Myc is known to induce the expression of
cluster of differentiation 47 (CD47), an innate immune
regulator, and programmed death-ligand 1 (PD-L1), an
adaptive immune checkpoint protein, involved in sup-
pressing the antitumor immune response [234]. Hence,
we believe that lncRNAs regulated by c-Myc might also
modulate the immune response in leukemia.
Recent evidence also suggests a crucial role of cir-
cRNAs in immune modulation and leukemia develop-
ment. The presence of fusion circRNAs (F-circRNAs)
has been shown in PML/RARα positive APL and MLL/
AF9 positive AML cells [58]. These F-circRNAs not only
caused cellular transformation by activating PI3K and
MAPK signaling but also contributed to leukemia cell
proliferation, survival, progression and therapy resistance
in vivo [58]. Since immune cells also regulates cell prolif-
eration, survival and confer resistance to therapy, we be-
lieve that oncogenic F-circRNAs might also be involved
in modulating the host immune system in leukemia, giv-
ing a survival advantage to leukemia cells. Because the
presence of circRNAs has also been detected in extracel-
lular vesicles [91], these circRNAs may modulate TME
through cell-to-cell communication, although this is yet
to be experimentally proven. Another circRNA, hsa_
circ_0075001, has been detected in AML where its ex-
pression positively correlated with total NPM1 expres-
sion [60]. AML patients carrying a high expression of
hsa_circ_0075001 had lower expression of components
of the Toll-like receptor signaling pathway, suggesting
that this circRNA might be involved in the modulation
of the immune response in AML [60]. Another cir-
cRNA, circMYBL2, which is derived from the cell-
cycle checkpoint gene MYBL2, has been reported to
be highly expressed in FLT3-ITD mutation-positive
AML patients [235]. Depletion of circMYBL2 inhib-
ited proliferation and induced differentiation of FLT3-
ITD AML cells in vitro and in vivo [235]. In a recent
study of a comprehensive analysis of circRNA expres-
sion during hematopoiesis, the expression of circRNA
was found to be highly cell-type specific during
hematopoietic differentiation [236]. All these studies
highlight the crucial role of circRNAs in immune
modulation in leukemias.
Several miRNAs have been shown to modulate im-
mune checkpoint proteins in various human malignan-
cies, including leukemia. In AML, miR-34 regulates PD-
L1 expression by targeting PD-L1 mRNA, thereby con-
trolling PD-L1 specific T-cell apoptosis of human AML
cells [85]. The miR-17-92 cluster, which encodes six
miRNAs including 17, 18a, 19a, 20a, 19b-1, and 92–1, is
also known to regulate T-cell responses in graft-versus-
host disease (GVHD) post allogeneic bone marrow
transplantation in mice [237]. This miRNA cluster has
been found to promote CD4 T-cell activation, expan-
sion, migration and Th1 differentiation while suppress-
ing Th2 and Treg differentiation. Inhibition of miR-17
or miR-19b significantly inhibited alloreactive T-cell ex-
pansion and IFN-γ secretion, leading to prolonged sur-
vival in recipient mice with GVHD while preserving the
graft-versus-leukemia effect [237]. Overexpression of
miR-125a-5p has been shown to induce granulocytic dif-
ferentiation, whereas miR-17-92 has the opposite effect
in APL cells [238]. A recent study has identified overex-
pression of miR-708 in AML patients, which delayed
HOXA9 mediated transformation in vivo by modulating
myeloid differentiation [239]. The authors concluded
that miR-708 is an indirect regulator of the HOX pro-
gram during normal and impaired hematopoiesis [239].
Clinical significance of ncRNAs in leukemia
In the current exploratory genomic era, the cellular or
extracellular level of noncoding RNAs (ncRNAs) are ad-
vancing for their roles in risk stratification, diagnosis,
and prognosis. Biologically ncRNAs regulate different
processes such as proliferation, apoptosis, stemness, and
differentiation. The clinical significance of ncRNAs in
leukemia broadly illustrates their capability for risk
stratification, diagnosis, and prognosis [212, 240, 241].
The quantitative assessments of transcripts by highly
sensitive assay (qPCR) for minimal residual disease de-
tection make ncRNA as a suitable candidate biomarker.
The residual transcript copies play a significant role in
detecting minimal residual disease. The best analogy is
BCR-ABL international scale detection for deep molecu-
lar and ultra-deep molecular response in Philadelphia
positive leukemias.
The prerequisite for ncRNAs as biomarkers in
leukemia is their aberrant expression in leukemic pheno-
type., A plethora of differential miRNA, lncRNA and cir-
cRNAs from high throughput data, supported the notion
and met this primary concern. However, leukemia itself
is a disease of heterogeneous cell population; therefore,
precisely identifying the robust biomarker in variable
data sets of different leukemia subtype is very challen-
ging at the validation step. Furthermore, the ncRNA
fine-tune the cellular homeostasis; therefore their regula-
tory function activated with a slight change in the onco-
genic molecular thrust. The ncRNAs modulates and
attempt to reconcile the abnormal molecular changes.
Recently, three-lncRNA expression-based risk score was
developed based on RNA-seq data for AML patients
using two leading data repositories [Therapeutically
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Available Research to Generate Effective Treatments
(TARGET) and The Cancer Genome Atlas (TCGA)].
According to prognosis modelling, which was developed
based on survival data, the combination of the lncRNA
risk score and cytogenetics risk group provided a higher
prognostic value than any of the individual prognostic
factor [61].
Acute myeloid leukemia is a heterogenous malignancy
of defective stem cells with impaired proliferation and
differentiation. Many regulatory ncRNAs largely regulate
the deregulation, stemness, proliferation and differenti-
ation. Various studies have proved that many deregu-
lated miRNAs are correlated with acute leukemia as
compared to control samples. Table 1 shows a list of sig-
nificant ncRNAs (lncRNA and circRNAs) for their
pathological and clinical significance in leukemia.
HOTAIRM1 is located between HOXA1 and HOXA2
gene cluster and regulate granulocytic differentiation in
hematopoiesis. High HOTAIRM1 expression results in
increased expression of HOXA4 gene expression and de-
fective myelopoiesis. HOTAIRM1 knockdown experi-
ments on NB4 cells correlated with low expression of
HOXA1 and HOXA4 cluster genes and block the ex-
pression of CD11b and CD18 during granulopoiesis.
HOTAIRM1 expression is activated by all-trans retinoic
acid, which induces the differentiation of myeloid pro-
genitor cells to granulocytes and mature myeloid cells
[53]. HOTAIRM1 transcript also interacts and form
complexes with transcripts of other key chromatin struc-
ture modulating proteins such as CBX1, PRC1 and
PRC2 [242]. HOTAIRM1 was overexpressed in NPM1-
mutated AML. Furthermore amongst, 215, intermediate
cytogenetics risk group AML patients, high HOTAIRM1
expression was associated with inferior overall survival
(OR: 2.04; P = 0.001) and disease-free survival (OR:2.56;
P < 0.001) and a higher cumulative incidence of relapse
(OR:1.67; P = 0.046). Furthermore, high expression of
HOTAIRM1 was associated with poor survival outcome
in the subgroup of NPM1 mutation-positive AML pa-
tients [54]. HOXA-AS2: HOXA cluster antisense RNA 2
(HOXA-AS2) located between HOXA3 and HOXA4
genes in the HOXA cluster. Like HOTAIR and
HOTAIRM1, HOXA-AS2 regulates differentiation of
myeloblasts to mature granulocytes and myeloid cells
[243]. Dong et al. proved the important role of HOXA-
AS2 in chemoresistance of myeloblast and the lncRNA
HOXA-AS2 could act as a therapeutic target for over-
coming resistance to chemotherapy in AML [96].
DLEU1 and DLEU2 lncRNA mapped on the frequently
deleted region of chromosome 3q14.3 region in lymph-
oma and leukemia. DLEU2 lncRNA act as pre miRNA
for 15a and 16–1 and both are involved in the pathogen-
esis of CLL through NF-kβ activity [222, 223]. LincRNA-
p21 in CLL is associated with p53 gene repression;
thereby, it acts as tumor suppressor gene, and this find-
ing was confirmed in 68 CLL patients, 62 MM patients
when compared with 36 healthy controls. The correl-
ation of p53 repression through LincRNA-p21 makes it
eligible therapeutic and prognostic marker in CLL pa-
tients [216, 244].
BGL3 lncRNA regulates the oncogenic expression of
BCR-ABL fusion gene through c-Myc mediated signal-
ing. The expression of BGL3 gene was inversely regu-
lated through miR-17, miR-93, miR-20a, miR-20b, miR-
106a, and miR-106b in Philadelphia positive ALL and
CML patients [57, 245].
Non-coding microRNAs (miRNAs) are posttranscrip-
tional and posttranslational regulators of the target
genes and proteins, respectively. The expression and
modulation of target genes is disease and tissue-specific.
In leukemia, miRNA expression signature depends upon
the disease subtype, cytogenetic risk group, age and mo-
lecular lesions like fusion genes or various mutations in
a gene like FLT3, cKIT, NPM1, BCR-ABL, MLL re-
arrangement. The most frequently deregulated miRNAs
in CML include miR-10a, miR-17/92, miR-150, miR-203,
and miR-328. Oncogenic role of miR-9 was suggested by
Chen et al. in the subgroup of AML patients with mixed
lineage leukemia (MLL)-rearrangement [246]. However,
Emmrich et al. suggested tumor suppressor role and ex-
pression was down-regulated in pediatric AML with t (8;
21) translocation [247]. A similar finding was observed
in Fu et al. that miR-9-1 was down-regulated in t (8;21)
AML patients [248]. Many recent studies have compiled
the biological and clinical significance of miRNAs in
acute and chronic leukemia [10, 240, 241].
Like lncRNA and miRNA, circular RNAs (circRNAs)
express as housekeeping, and regulatory RNAs. The
mode of action of circRNA may be autocrine or para-
crine; therefore, these circRNAs have been detected in
various body fluids. The circRNAs are stable in different
body fluids like saliva, urine, blood, and CSF. The basal
level of various circRNAs is crucial to explore for under-
standing their clinical significance. In leukemia, ultra-
deep genomic data is available, which enabled to explore
different ncRNA entities for their diagnostic and prog-
nostic significance. Various types of circRNAs have been
characterized based on their position in the gene, the in-
tron origin circRNA and exonic circRNAs, intergenic
circRNAs, and exon-intron circRNAs. Although, a vari-
ous study has supported the notion of differential cir-
cRNA expression profile in leukemia but the validation
data from experimental studies is limited.. The origin of
circRNAs has been associated with fusion genes in
leukemia [249]. Isolated studies have shown the role of
following cirRNAs, f-circPR, f-circM9, hsa_circ_0075001,
circ-ANAPC7, circ-100,290, circPAN3, circ_0009910,
circ-HIPK2, circ-DLEU2, has_cir_0004277, circPVT1 in
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AML [59, 71, 250–252]. In CML, the direct association
of circBA9.3 with BCR-ABL tyrosine kinase activity was
observed in CML patients. The high expression of cir-
cBA9.3 was associated with cell proliferation and inverse
relations with apoptosis. Furthermore, the high expres-
sion was associated with relapse and disease progression
suggesting the possible role of circBA9.3 as a potential
therapeutic marker in CML [72].
Conclusions & future perspectives
The crucial role of ncRNAs in the gene regulatory net-
works and recent progress in the field of genomics and
biotechnology has made them a favorable therapeutic
targeting agent in cancer. lncRNAs and circRNAs act
through various mechanisms as compared to miRNAs in
cancer, and so targeting them can help in exploring
more critical mechanisms involved in tumorigenesis.
This review highlights the therapeutic potential of
ncRNAs such as miRNAs, lncRNAs and circRNAs in
leukemia and culminates the significance of these bio-
molecules as they improved the prognostic risk stratifi-
cation in leukemia. The improvement in risk
stratification has led to the generation of medical algo-
rithms that can help in standardizing selection and treat-
ment planning based on the molecular profile of the
patient. These risk stratification schemes can be taken
one step further by the inclusion of selected ncRNA ex-
pression profiles.
Additionally, by artificially modulating the expression
of ncRNAs, the therapeutic sensitivity to conventional
chemotherapy can be restored. In this regard, miRNAs
have become the most extensively studied ncRNAs in
leukemia because of their role as an oncogene and
tumor suppressor in various cancers, including leukemia
and their involvement in the regulation of post-
transcriptional processes. The advanced genomic ap-
proaches, such as CRISPR-Cas9 technology is used to
identify functionally relevant miRNA-mRNA target pairs
that regulate leukemia (e.g., AML) cell line growth and
will likely prove beneficial for preclinical models. An-
other approach is the use of miRNA mimics or modified
miRNAs as RNA based drugs to target ncRNAs and
mRNAs. Silencing of aberrant miRNAs can also be
achieved by miRNA sponges and anti-miRNA oligonu-
cleotides (AMOs). Finally, miRNA analysis through ad-
vanced next-generation sequencing will provide more
details on the involvement of ncRNAs in the onset and
progression of leukemia. For efficient miRNA-based
therapy, improvised miRNA delivery vehicles with higher
stability and less toxicity must be developed.
On the other hand, oncogenic lncRNAs can be tar-
geted using siRNAs by packaging them in nanoparticle
vectors for efficient targeting. In addition, high affinity
or stability of antisense oligonucleotides can be achieved
by synthetically modifying themto reduce the oncogenic
lncRNAs by alternative splicing, modulation of RNA and
protein interactions or by degrading them. Further, lenti-
viral vectors can be used as an efficient method for the
transportation of RNA products into tissues as they aid
in stable transfection by efficiently inserting the siRNA
sequence into target cells.
Regarding the many roles of ncRNAs in cancer, there
are still many challenges that must be resolved in order
to improve the potential of ncRNAs as a potential thera-
peutic target in cancer. As the complex microenviron-
ment of the cell makes the delivery of ncRNAs very
challenging and difficult, the efficient delivery system
with minimal toxicity is vital. It is suggested that the
drug delivery can be improved by using two or more dif-
ferent carriers for targeting ncRNAs, for example com-
bining nano designs with organ-specific response
receptor. Moreover, in order to increase their bioavail-
ability, different ways must be discovered to reduce RNA
degradation. Although the field of ncRNAs is well stud-
ied, their role as a biomarker and as a therapeutic target
in cancer is yet to be explored in detail. Many clinical
trials are currently underway, and if some of the chal-
lenges mentioned above are addressed appropriately,
then we would likely see ncRNAs emerging as a novel
target for cancer therapy.
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